Neoventa Medical AB

Neoventa Medical AB is a Swedish company dedicated to advancing fetal monitoring technologies, specializing in non-invasive solutions to enhance prenatal care for healthcare providers. Founded in Molndal, Sweden, Neoventa Medical AB develops innovative technologies for fetal monitoring. The company secured funding on June 19, 2006, raising SEK 75 million from Patricia Industries, Russia Growth, and SEB Venture Capital. The current CEO is Ulf Jaernberg, who leads the firm in its mission to enhance maternal and fetal health.

Neoventa Medical specializes in innovative solutions for fetal monitoring, particularly through its flagship product, the Stan S41. This continuous monitoring device offers superior insights into fetal health during labor, distinguishing itself from traditional pH measurements in fetal blood. The Stan S41 integrates unique ST segment analysis with continuous electrocardiogram (ECG) monitoring, providing critical information on the fetus’s acid-base balance and heart rate patterns. Neoventa's products cater primarily to hospitals and clinics across Europe, the Middle East, Asia, and Africa, enhancing obstetricians' and gynecologists' ability to manage labor and delivery effectively.

In 2022, Neoventa Medical reported revenue of SEK 6,788,561. 90 and an EBITDA of SEK 392,900. 70. The company operates on a B2B model, selling medical devices like the Stan S41 and Goldtrace™ fetal spiral electrode to healthcare providers, emphasizing long-term relationships and supporting bulk purchases.

Neoventa Medical plans to leverage the SEK 75 million raised in June 2006 to expand its product line and market reach. The company aims to develop new products tailored for advanced fetal monitoring solutions, targeting the European and Asian markets for entry by 2025. This funding will support research, development, and marketing efforts for these initiatives.